[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-336427-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-336427-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","biological-and-therapeutic-insights-from-animal-modeling-of-fusion-driven-pediatric-soft-tissue-sarcomas","Biological and therapeutic insights from animal modeling of fusion-driven pediatric soft tissue sarcomas","","Children’s cancer survival has improved through decades of refinements in surgery, radiation, and chemotherapy, yet recurrent disease and poor outcomes remain common. Fusion-driven pediatric soft tissue sarcomas arise from chromosomal translocations producing a chimeric, near “monogenic” fusion oncogene, enabling in vivo animal modeling. Focusing on transgenic tumor models covering multiple sarcoma subtypes, the Review shows that fusion oncogenes require specific cellular states or developmental timing, yielding distinct tumorigenic outcomes. Cross-lineage comparison highlights dependencies on chromatin regulators and developmental pathway co-option to reveal targetable mechanisms and improve therapy decisions.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/biological-and-therapeutic-insights-from-animal-modeling-of-fusion-driven-pediatric-soft-tissue-sarcomas/336427/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/biological-and-therapeutic-insights-from-animal-modeling-of-fusion-driven-pediatric-soft-tissue-sarcomas/336427.png","ImageObject",300,407,{"name":42,"@type":43},"Maeve","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are fusion-driven pediatric soft tissue sarcomas well suited to animal modeling?","Question",{"text":63,"@type":64},"They are defined by chromosomal translocations that generate a chimeric fusion oncogene. This distinctive genetic feature makes it possible to introduce the oncogene into animal systems to study tumorigenesis in vivo.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do fusion oncogenes influence tumor development in different pediatric sarcoma contexts?",{"text":68,"@type":64},"Fusion oncogenes produce different outcomes depending on lineage and the timing of expression. Pediatric tumorigenesis depends on the presence of a specific cellular state or developmental stage.",{"name":70,"@type":61,"acceptedAnswer":71},"What biological dependencies are highlighted across these fusion-driven cancers?",{"text":72,"@type":64},"Broadly, these cancers rely on chromatin regulators to support oncogenic gene expression and to co-opt developmental pathways. Comparative analyses across models aim to identify mechanisms that can be targeted therapeutically.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},336427,1790198488,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},5909877438554,"https://ap-avatar.wpscdn.com/avatar/5600025385ad2bf12a7?_k=1778553567797529272","© 2024 . Published by The Company of Biologists Ltd | Disease Models & Mechanisms (2024) 17, dmm050704 . doi:10 . 1242/dmm.050704  \nREVIEW SPECIAL ISSUE  \nTRANSLATING MULTISCALE RESEARCH IN RARE DISEASE  \nBiological and therapeutic insights from animal modeling of fusion-driven pediatric soft tissue sarcomas  \nJack P. Kucinski1,2,*, Delia Calderon1,2,* and Genevieve C. Kendall1,2,3,‡  \nABSTRACT  \n\n| Survival for children with cancer has primarily improved over the past decades due to refinements in surgery, radiation and chemotherapy. Although these general therapies are sometimes curative, the cancer often recurs, resulting in poor outcomes for patients. Fusion-driven pediatric soft tissue sarcomas are genetically defined by chromosomal translocations that create a chimeric oncogene. This distinctive, almost ‘monogenic’, genetic feature supports the generation of animal models to study the respective diseases in vivo. This Review focuses on a subset of fusion-driven pediatric soft tissue sarcomas that have transgenic animal tumor models, which includes fusion-positive and infantile rhabdomyosarcoma, synovial sarcoma, undifferentiated small round cell sarcoma, alveolar soft part sarcoma and clear cell sarcoma. Studies using the animal models of these sarcomas have highlighted that pediatric cancers require a specific cellular state or developmental stage to drive tumorigenesis, as the fusion oncogenes cause different outcomes depending on their lineage and timing of expression. Therefore, understanding these context-specific activities could identify targetable activities and mechanisms critical for tumorigenesis. Broadly, these cancers show dependencies on chromatin regulators to support oncogenic gene expression and coopting of developmental pathways. Comparative analyses across lineages and tumor models will further provide biological and therapeutic insights to improve outcomes for these children.\u003Cbr>KEY WORDS: Fusion Oncogene, Pediatric oncology, Sarcoma, Transgenic animal models |\n| --- |\n| Introduction\u003Cbr>Pediatric cancers are a devastating diagnosis and result in an unacceptable annual loss of 10-20 million years of expected life globally (Alvarez et al., 2022; Force et al., 2019) . Overall outcomes for children with cancer have improved through the decades, largely due to refinements in surgery, radiation and first-line chemotherapeutic agents (Hudson et al., 2014) . However, pediatric cancer survivors face adverse long-term health effects |\n\n1Center for Childhood Cancer Research, The Abigail Wexner Research Institute, Nationwide Children’s Hospital, Columbus, OH 43215, USA. 2Molecular, Cellular, and Developmental Biology PhD Program, The Ohio State University, Columbus, OH 43210, USA. 3Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH 43215, USA.  \n*These authors contributed equally to this work  \n‡Author for correspondence ([genevieve.kendall@nationwidechildrens.org](genevieve.kendall@nationwidechildrens.org))  \n J. P. K. , 0000-0002-1788-1305; D. C. , 0000-0003-2393-022X; G. C. K. , 0000-0003- 3775-2006  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0](https://creativecommons.org/licenses/by/4.0n)[n](https://creativecommons.org/licenses/by/4.0n)), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.  \nand an increased risk of secondary cancer formation due to treatment toxicity (Hudson et al., 2014; Suh et al., 2020). Therefore, there is a critical unmet need for targeted therapies to improve outcomes for these children and minimize negative off-target effects and lifelong consequences. Pediatric cancers often have a low mutational burden compared to that of adult tumors, and tumor histology reflects features of abnormal development (Thatikonda et al., 2023; Gröbner et al., 2018; Filbin and Monje, 2019","cbCaibTMrwMXhZBH","https://ap.wps.com/l/cbCaibTMrwMXhZBH","pdf",810197,18,"English","# Introduction\n## Background on pediatric cancer outcomes\n## Rationale for fusion oncogene animal models\n## Focus of the Review and sarcoma subtypes\n# Fusion oncogene-driven rhabdomyosarcoma\n## Clinical presentation\n## Molecular drivers and modeling approach","[{\"question\":\"Why are fusion-driven pediatric soft tissue sarcomas well suited to animal modeling?\",\"answer\":\"They are defined by chromosomal translocations that generate a chimeric fusion oncogene. This distinctive genetic feature makes it possible to introduce the oncogene into animal systems to study tumorigenesis in vivo.\"},{\"question\":\"How do fusion oncogenes influence tumor development in different pediatric sarcoma contexts?\",\"answer\":\"Fusion oncogenes produce different outcomes depending on lineage and the timing of expression. Pediatric tumorigenesis depends on the presence of a specific cellular state or developmental stage.\"},{\"question\":\"What biological dependencies are highlighted across these fusion-driven cancers?\",\"answer\":\"Broadly, these cancers rely on chromatin regulators to support oncogenic gene expression and to co-opt developmental pathways. Comparative analyses across models aim to identify mechanisms that can be targeted therapeutically.\"}]","Biological and therapeutic insights from animal modeling of fusion-driven pediatric soft tissue sarcomas | PDF",1790015005,45,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/458627f914614ae2b6d5584f4700777a.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7d215b764f2c950f8c42c7ce8307b962.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f9fe7a1eeb1bd7b197d304f4a0b2d621.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cb2a11392e435ad7f2dc5158ada31cde.webp",980,1268]